{"title":"太极汤对血脂异常的影响:系统回顾与meta分析","authors":"Yeong-seo Lee, Tae-young Huh, Kyoung-min Kim","doi":"10.22246/jikm.2023.44.3.485","DOIUrl":null,"url":null,"abstract":"Objective: The purpose of this study is to assess the effectiveness and safety of using Taeksa-tang for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs).Methods: The search was conducted using keywords such as “dyslipidemia”, “hyperlipidemia”, “taeksa tang”, “zexie tang”, and “takusha to” in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane’s risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web.Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (Taeksa-tang or Taeksa-tang-gagam) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008).Conclusion: This study suggests that Taeksa-tang is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.","PeriodicalId":22826,"journal":{"name":"The Journal of Internal Korean Medicine","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Effect of Taeksa-tang for Dyslipidemia: A Systematic Review and Meta-Analysis\",\"authors\":\"Yeong-seo Lee, Tae-young Huh, Kyoung-min Kim\",\"doi\":\"10.22246/jikm.2023.44.3.485\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: The purpose of this study is to assess the effectiveness and safety of using Taeksa-tang for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs).Methods: The search was conducted using keywords such as “dyslipidemia”, “hyperlipidemia”, “taeksa tang”, “zexie tang”, and “takusha to” in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane’s risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web.Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (Taeksa-tang or Taeksa-tang-gagam) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008).Conclusion: This study suggests that Taeksa-tang is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.\",\"PeriodicalId\":22826,\"journal\":{\"name\":\"The Journal of Internal Korean Medicine\",\"volume\":\"13 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of Internal Korean Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22246/jikm.2023.44.3.485\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Internal Korean Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22246/jikm.2023.44.3.485","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究旨在通过随机对照试验(rct)的系统评价和荟萃分析,评价太极沙汤治疗血脂异常的有效性和安全性。方法:于2023年4月13日在Pubmed、Cochrane、Embase、ScienceDirect、CNKI、万方、CiNii、RISS、KISS、ScienceON、OASIS、DBpia等12个数据库中以“血脂异常”、“高脂血症”、“taeksa tang”、“泽泻tang”、“takusha to”等关键词进行检索。对出版期限和语言没有限制。采用Cochrane偏倚风险(RoB)评价研究质量。使用Review Manager网站,根据总有效率(TER)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)和不良反应等结果测量进行meta分析。结果:共选择9项rct。在评价RoB时,2项提及随机序列产生的研究、1项双盲研究和8项无缺失值的研究被评价为低风险,1项未提及随机序列产生的研究被评价为高风险。其他部分均被评估为风险不明确。治疗组(太白汤或太白汤加甘)在TER (RR: 1.24, 95% CI 1.15 ~ 1.34, P<0.00001)、TC (MD: -1.12, 95% CI -1.68 ~ -0.56, P<0.0001)、TG (MD: -1.08, 95% CI -1.65 ~ -0.51, P=0.0002)、HDL-C (MD: 0.63, 95% CI 0.34 ~ 0.93, P<0.0001)、LDL-C (MD: -0.81, 95% CI -1.10 ~ -0.53, P<0.00001)方面的疗效均较对照组(西药或中成药)有统计学意义。治疗组不良反应明显低于对照组(RR: 0.30, 95% CI 0.12 ~ 0.74, P=0.008)。结论:太极沙汤治疗血脂异常是一种安全有效的方法。然而,由于纳入的研究质量较低,未来需要进行更多的临床研究,以增加临床应用的可能性。
The Effect of Taeksa-tang for Dyslipidemia: A Systematic Review and Meta-Analysis
Objective: The purpose of this study is to assess the effectiveness and safety of using Taeksa-tang for dyslipidemia through a systematic review and meta-analysis of randomized controlled trials (RCTs).Methods: The search was conducted using keywords such as “dyslipidemia”, “hyperlipidemia”, “taeksa tang”, “zexie tang”, and “takusha to” in 12 databases (Pubmed, Cochrane, Embase, ScienceDirect, CNKI, Wanfang, CiNii, RISS, KISS, ScienceON, OASIS, and DBpia) on April 13, 2023. There were no limits on the publication period and language. Cochrane’s risk of bias (RoB) was used to evaluate the quality of the studies. A meta-analysis was conducted according to the outcome measurements such as total effective rate (TER), total cholesterol (TC), triglyceride (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and adverse effects, using the Review Manager web.Results: A total of 9 RCTs were selected. In evaluating the RoB, 2 studies mentioning the random sequence generation, 1 study conducting double blindness, and 8 studies without missing values were evaluated as low risk, while 1 study without mentioning the random sequence generation was evaluated as high risk. All other parts were evaluated as unclear risk. The treatment group (Taeksa-tang or Taeksa-tang-gagam) showed more statistically significant effects compared to the control group (Western medicine or Chinese patent medicine) in TER (RR : 1.24, 95% CI 1.15 to 1.34, P<0.00001), TC (MD : -1.12, 95% CI -1.68 to -0.56, P<0.0001), TG (MD : -1.08, 95% CI -1.65 to -0.51, P=0.0002), HDL-C (MD : 0.63, 95% CI 0.34 to 0.93, P<0.0001), LDL-C (MD : -0.81, 95% CI -1.10 to -0.53, P<0.00001). In addition, the treatment group showed lower adverse effects compared to the control group (RR : 0.30, 95% CI 0.12 to 0.74, P=0.008).Conclusion: This study suggests that Taeksa-tang is effective and safe to use for treating dyslipidemia. However, due to the low quality of the included studies, more clinical studies need to be conducted in the future to increase the possibility of clinical use.